"
Ivermectin Suitable for All Treatment Stages
Since early on, the Frontline COVID-19 Critical Care Alliance (FLCCC) has been trying to get the truth out about ivermectin. The FLCCC's prophylaxis and early outpatient COVID-19 protocol is known as I-MASK+22 while the hospital treatment is called I-MATH+.23 All include ivermectin. As noted by the FLCCC in a news release:24
"The data shows the ability of the drug Ivermectin to prevent COVID-19, to keep those with early symptoms from progressing to the hyper-inflammatory phase of the disease, and even to help critically ill patients recover.
… numerous clinical studies — including peer-reviewed randomized controlled trials — showed large magnitude benefits of Ivermectin in prophylaxis, early treatment and also in late-stage disease. Taken together … dozens of clinical trials that have now emerged from around the world are substantial enough to reliably assess clinical efficacy."
FLCCC president and chief medical officer Dr. Pierre Kory has testified to the benefits of ivermectin before a number of COVID-19 panels, including the Senate Committee on Homeland Security and Governmental Affairs in December 202025 and the National Institutes of Health COVID-19 Treatment Guidelines Panel in January 2021.26
The two protocols — I-MASK+27 and I-MATH+28 — are available for download on the FLCCC Alliance website in multiple languages. The clinical and scientific rationale for the I-MATH+ hospital protocol has also been peer-reviewed and was published in the Journal of Intensive Care Medicine29 in mid-December 2020.
Strong Evidence for Ivermectin
April 24 through 25, 2021, Dr. Tess Lawrie, director of Evidence-Based Medicine Consultancy Ltd.,30 hosted the first International Ivermectin for COVID Conference online.31
Twelve medical experts32 from around the world — including Kory — shared their knowledge, reviewing mechanism of action, protocols for prevention and treatment, including so-called long-hauler syndrome, research findings and real world data. All of the lectures, which were recorded via Zoom, can be viewed on Bird-Group.org.33
A one-page summary of the clinical trial evidence for ivermectin is available on the FLCCC website,34 while a listing of all ivermectin trials done to date, with links to the published studies, can be found on c19Ivermectin.com.35 So, what does the evidence show? In summary, studies have demonstrated ivermectin:36
• Lowers viral load.
• Inhibits replication of many viruses, including SARS-CoV-2 and seasonal influenza viruses. An observational study37 from Bangladesh, which looked at ivermectin as a pre-exposure prophylaxis for COVID-19 among health care workers, found only four of the 58 volunteers who took 12 mg of ivermectin once per month for four months developed mild COVID-19 symptoms, compared to 44 of the 60 health care workers who had declined the medication.
• Inhibits inflammation through several pathways and protects against organ damage.
• Prevents transmission of SARS-CoV-2 when taken before or after exposure.
• Speeds recovery and lowers risk of hospitalization and death in COVID-19 patients — The average reduction in mortality, based on 18 trials, is 75%.38 A WHO-sponsored review39 suggests ivermectin can reduce COVID-19 mortality by as much as 83%.
Who's Actually Following the Science?
As noted in an August 3, 2021, review paper in New Microbes New Infections, titled "Ivermectin: A Multifaceted Drug of Nobel-Prize Honored Distinction With Indicated Efficacy Against a New Global Scourge, COVID-19":40
"In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honored the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world's most devastating tropical diseases.
Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls.
During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with the extent of IVM distributions in all 25 states with p < 0.002.
Sharp reductions in morbidity using IVM were also observed in two animal models, of SARS-CoV-2 and a related betacoronavirus. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains."
Despite the evidence, the American Medical Association (AMA), the American Pharmacists Association (APhA) and the American Society of Health-System Pharmacists (ASHP) are now banding together to call on doctors to immediately stop prescribing ivermectin for COVID outside of clinical trials.41
Hopefully, doctors will evaluate the evidence for themselves and do what makes sense and is best for their patients, rather than cater to Big Pharma. Indeed, as the U.S. wants to eliminate all use of ivermectin, other countries are starting to use more of it. India, for example, has added ivermectin for COVID-19 to its list of essential medicines.
The Tokyo Metropolitan Medical Association also added ivermectin to its home treatment protocol August 13, 2021, and Indonesia's government not only authorized the use of the drug but also created a website showing real-time availability of the drug. Hospitals in Indonesia started using ivermectin July 22, 2021. By the first week of August, cases and deaths were plummeting.42"
- Dr. Joseph Mercola